Real-world data regarding the effectiveness, safety and immunogenicity of the Pfizer-BioNTech BNT162b2 mRNA vaccine are accumulating in the literature, suggesting that this vaccine generates high titres of S1-binding IgG antibodies that exhibit potent virus neutralization capacity. This is the first phase IV immunogenicity study to recruit a large number of Greek healthcare workers (=425) including 63 previously-infected subjects. We measured titres of neutralizing IgGs against the receptor-binding domain of the S1 subunit of the spike protein of SARS-CoV-2 14 days post-immunization with the first dose, employing the SARS-CoV-2 IgG II Quant assay. A total of 92.24 % of our study cohort received a positive assay outcome and titres varied with age. Post-hoc analysis revealed that although titres did not significantly differ among participants aged 20-49 years, a significant decline was marked in the age group of 50-59 years, which was further accentuated in subjects aged over 60. Antibody titres escalated significantly among the previously-infected, indicating the potential booster effect of the first dose in that group.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513631 | PMC |
| http://dx.doi.org/10.1099/jmm.0.001387 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Cohort of Healthcare Workers.
Cureus
December 2024
Internal Medicine, Fundació Assistencial Mútua Terrassa, Terrassa, ESP.
In this 13-month follow-up study, we examined a cohort of vaccinated healthcare workers without prior SARS-CoV-2 infection to assess the humoral and cellular response to the BNT162b2 mRNA COVID-19 vaccine over time. We measured median immunoglobulin G and lymphocyte subpopulation levels after the first and second doses, at five months post-second dose, and before and after the third dose. Our findings evinced a remarkable initial cellular and humoral response to each vaccine dose, although a progressive decline suggests the potential need for long-term booster doses.
View Article and Find Full Text PDFSelf-reported longitudinal COVID-19 vaccination reactogenicity profiles in persons with multiple sclerosis.
Mult Scler Relat Disord
December 2024
Accelerated Cure Project for MS, Waltham, MA 02451, USA. Electronic address:
Background: Preventing severe COVID-19 associated outcomes continues to be a priority for persons with multiple sclerosis (PwMS). We previously reported in an interim analysis that short-term reactions to the first and second SARS-CoV-2 vaccines experienced by PwMS were mostly self-limiting and similar to reactions experienced by the general population.
Objectives: First, to report short-term reactogenicity experienced by PwMS in relation to the first through fourth SARS-CoV-2 vaccines.
The guided fire from within: intratumoral administration of mRNA-based vaccines to mobilize memory immunity and direct immune responses against pathogen to target solid tumors.
Cell Discov
January 2025
School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
We investigated a novel cancer immunotherapy strategy that effectively suppresses tumor growth in multiple solid tumor models and significantly extends the lifespan of tumor-bearing mice by introducing pathogen antigens into tumors via mRNA-lipid nanoparticles. The pre-existing immunity against the pathogen antigen can significantly enhance the efficacy of this approach. In mice previously immunized with BNT162b2, an mRNA-based COVID-19 vaccine encoding the spike protein of the SARS-CoV-2 virus, intratumoral injections of the same vaccine efficiently tagged the tumor cells with mRNA-expressed spike protein.
View Article and Find Full Text PDFReduced durability of hybrid immunity to SARS-CoV-2 in immunocompromised children.
Front Immunol
January 2025
Program of Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
Background: In endemic COVID-19, immunocompromised children are vulnerable until vaccinated but the optimal primary vaccination regime and need for booster doses remains uncertain.
Methods: We recruited 19 immunocompromised children (post-solid organ transplantation, have autoimmune disease or were on current or recent chemotherapy for acute lymphoblastic leukemia), and followed them from the start of primary vaccination with BNT162b2 mRNA SARS-CoV-2 until 1-year post-vaccination. We investigated the quality of vaccine immunogenicity, and longevity of hybrid immunity, in comparison to healthy children.
The association between acute transverse myelitis and COVID-19 vaccination in Korea: Self-controlled case series study.
Eur J Neurol
January 2025
Department of Health Convergence, College of Science and Industry Convergence, Ewha Womans University, Seoul, Republic of Korea.
Background: Acute transverse myelitis (ATM) has been reported as a potential association between COVID-19 vaccination. In this study, we aimed to investigate the association between the COVID-19 vaccination and ATM.
Methods: A self-controlled case series study was performed using a large database that combine the COVID-19 vaccine registry and the national claims database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!